Chronic Kidney Disease Clinical Trial Landscape
Data updated: May 20, 2026
833 clinical trials tracked since 2008
Chronic Kidney Disease (CKD), also known as renal disease, refers to the gradual loss of kidney function over time, affecting a significant portion of the global population. Understanding the clinical trial landscape is crucial for monitoring advancements in CKD treatment and management. Since 2008, 826 CKD trials have been registered, with 156 currently active, meaning they are recruiting, enrolling, or active but not recruiting. The active trials are distributed across different phases of clinical development: 26 are in Phase 1, 60 in Phase 2, 47 in Phase 3, and 45 in Phase 4. The distribution suggests a strong focus on Phase 2 trials, exploring a range of potential therapeutic interventions. Industry sponsorship is led by AstraZeneca, with 8 active trials. Bayer and Eli Lilly each have 3 active trials, while Novo Nordisk and Boehringer Ingelheim each sponsor 2 active trials. This activity from major pharmaceutical players highlights the ongoing investment in developing new CKD therapies.
159 active
/
833 total (since 2008)
27
Phase 1 Active
168 total
62
Phase 2 Active
295 total
48
Phase 3 Active
243 total
45
Phase 4 Active
203 total
Top Industry Sponsors
Sorted by active Active Done Failed
AstraZeneca 8 18 3
Eli Lilly 3 8 1
Bayer 2 16 4
Novo Nordisk 2 6 1
Boehringer Ingelheim 2 3 1
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06268873 ACTIVE NOT RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
AstraZeneca n=2,554
NCT05457283 RECRUITING
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Bayer n=100
NCT06742723 RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca n=5,000
NCT07107945 RECRUITING
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Boehringer Ingelheim n=120
NCT05970172 RECRUITING
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Astellas Pharma Global Development, Inc. n=100
+ 238 more Phase 3 trials — see full database below
Chronic Kidney Disease — Trials Started by Year (last 10 years)
2016 41
2017 35
2018 30
2019 48
2020 35
2021 45
2022 33
2023 33
2024 41
2025 65
2026 32
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
AstraZeneca 29
Eli Lilly 12
Bayer 22
Novo Nordisk 9
Boehringer Ingelheim 6
Shaanxi Micot Pharmaceutical Technology Co., Ltd. 4
Kind Pharmaceuticals LLC 2
United Therapeutics 2
Amgen 18
Akebia Therapeutics 17
Active Trials by Phase
Phase 1 27
Phase 2 62
Phase 3 48
Phase 4 45
Enrollment Size Distribution
1-50 348
51-200 268
201-500 113
501-1k 38
1k+ 32
All Industry Sponsors
Sorted by active Active Done Failed
AstraZeneca 8 18 3
Eli Lilly 3 8 1
Bayer 2 16 4
Novo Nordisk 2 6 1
Boehringer Ingelheim 2 3 1
Shaanxi Micot Pharmaceutical Technology Co., Ltd. 2 2 0
Kind Pharmaceuticals LLC 2 0 0
United Therapeutics 2 0 0
Amgen 1 12 5
Akebia Therapeutics 1 12 4
Novartis 1 12 0
OPKO Health, Inc. 1 3 3
Renibus Therapeutics, Inc. 1 3 0
Iperboreal Pharma Srl 1 1 2
Humacyte, Inc. 1 3 0
NCT06268873 ACTIVE NOT RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
AstraZeneca n=2,554
NCT05457283 RECRUITING
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Bayer n=100
NCT07565701 NOT YET RECRUITING
Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis
Geoff Block n=100
NCT06742723 RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca n=5,000
NCT07107945 RECRUITING
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Boehringer Ingelheim n=120
NCT05970172 RECRUITING
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Astellas Pharma Global Development, Inc. n=100
NCT07355062 RECRUITING
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Renibus Therapeutics, Inc. n=150
NCT06383390 ACTIVE NOT RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company n=10,000
NCT07241390 RECRUITING
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Eli Lilly and Company n=7,140
NCT05196035 RECRUITING
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Bayer n=219
NCT03619850 RECRUITING
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
AMAG Pharmaceuticals, Inc. n=129
NCT07181135 ENROLLING BY INVITATION
FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors
University Medical Center Groningen n=180
NCT05746559 ACTIVE NOT RECRUITING
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Alexion Pharmaceuticals, Inc. n=736
NCT05021835 ACTIVE NOT RECRUITING
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
Novo Nordisk A/S n=6,200
NCT07494409 RECRUITING
A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia
Kind Pharmaceuticals LLC n=300
NCT07419828 RECRUITING
A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
Shandong Suncadia Medicine Co., Ltd. n=1,978
NCT07487727 RECRUITING
A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
Kind Pharmaceuticals LLC n=240
NCT06087835 ACTIVE NOT RECRUITING
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
AstraZeneca n=1,835
NCT03321656 RECRUITING
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
Roberto Gedaly n=78
NCT03994471 RECRUITING
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Iperboreal Pharma Srl n=170
NCT03323476 ACTIVE NOT RECRUITING
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
Centre Hospitalier Departemental Vendee n=136
NCT07020832 RECRUITING
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Apellis Pharmaceuticals, Inc. n=320
NCT03633708 RECRUITING
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Amgen n=56
NCT07425262 NOT YET RECRUITING
A Pilot Trial of Chinese Medicine for Patients With Dialytic Hypotension
Chang Gung Memorial Hospital n=100
NCT07025629 RECRUITING
Dapagliflozin for Cardio-renal Protection After ICU Discharge
Assistance Publique - Hôpitaux de Paris n=600
NCT06901505 ACTIVE NOT RECRUITING
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Akebia Therapeutics n=353
NCT06933472 RECRUITING
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
Alebund Pharmaceuticals n=264
NCT05422534 RECRUITING
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
Vanderbilt University Medical Center n=156
NCT07296146 NOT YET RECRUITING
Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.
Badr University n=80
NCT05732727 RECRUITING
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
University Hospital, Tours n=720
NCT05546099 RECRUITING
Patient-driven Management of BP in CKD
VA Office of Research and Development n=160
NCT07122401 RECRUITING
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
Shaanxi Micot Pharmaceutical Technology Co., Ltd. n=424
NCT06858280 RECRUITING
Patiromer and Diet/hrQoL in Chronic Dialysis
Mario Negri Institute for Pharmacological Research n=40
NCT07119372 RECRUITING
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Biocad n=228
NCT06908473 ENROLLING BY INVITATION
Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients
Guangdong Provincial Hospital of Traditional Chinese Medicine n=530
NCT06998862 RECRUITING
Colchicine in Chronic Kidney Disease Patients
Hospital General Universitario Gregorio Marañon n=744
NCT06982079 RECRUITING
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Ain Shams University n=60
NCT03565913 ACTIVE NOT RECRUITING
Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V
University of Texas Southwestern Medical Center n=269
NCT05339139 RECRUITING
SAfety of Regional Citrate Anticoagulation (SARCA Study)
Fresenius Medical Care North America n=50
NCT06801886 ENROLLING BY INVITATION
Silymarin's Advantage on Graft Effectiveness
University Hospital, Martin n=130
NCT05908084 RECRUITING
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Humacyte, Inc. n=150
NCT02984124 ACTIVE NOT RECRUITING
Communication During Hospitalization About Resuscitation Trial
University of Vermont n=182
NCT06329622 RECRUITING
Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease
Huashan Hospital n=58
NCT03418779 ACTIVE NOT RECRUITING
Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
Guang'anmen Hospital of China Academy of Chinese Medical Sciences n=60
NCT06352138 NOT YET RECRUITING
Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients
Megalabs n=280
NCT06466785 RECRUITING
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Genexine, Inc. n=429
NCT06421883 ENROLLING BY INVITATION
Study the Effect of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Level in Hemodialysis Patients
Al-Azhar University n=80
NCT05075408 COMPLETED
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Galderma R&D n=258
NCT05803421 COMPLETED
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company n=2,749
NCT03402386 COMPLETED
Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Tanabe Pharma Corporation n=42
NCT03461146 COMPLETED
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
Tanabe Pharma Corporation n=24
NCT03329196 COMPLETED
Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Tanabe Pharma Corporation n=304
NCT03439137 COMPLETED
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
Tanabe Pharma Corporation n=323
NCT02251431 COMPLETED
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Baylor Research Institute n=57
NCT04523727 SUSPENDED
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Keryx Biopharmaceuticals n=45
NCT05047263 COMPLETED
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
Bayer n=1,584
NCT04865770 COMPLETED
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Novo Nordisk A/S n=106
NCT07344922 COMPLETED
SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
Mansoura University n=100
NCT00772382 COMPLETED
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Tanabe Pharma Corporation n=116
NCT00858637 COMPLETED
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
Tanabe Pharma Corporation n=260
NCT04064827 TERMINATED
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
AbbVie n=2
NCT04649411 WITHDRAWN
Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
Keryx Biopharmaceuticals
NCT03183245 COMPLETED
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
Humacyte, Inc. n=242
NCT07030595 COMPLETED
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
Alebund Pharmaceuticals n=474
NCT05901831 COMPLETED
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Bayer n=241
NCT02513303 COMPLETED
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
Vascular Therapies, Inc. n=269
NCT05082571 WITHDRAWN
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
Akebia Therapeutics
NCT05082584 WITHDRAWN
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
Akebia Therapeutics
NCT05425056 COMPLETED
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
Vascular Therapies, Inc. n=136
NCT01220843 COMPLETED
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
Centre Hospitalier Universitaire, Amiens n=98
NCT06381076 COMPLETED
High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.
University of Florida n=35
NCT02859896 TERMINATED
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
Sanofi n=21
NCT05543928 TERMINATED
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
OPKO Health, Inc. n=2
NCT01219959 COMPLETED
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Vantive Health LLC n=71
NCT00567398 COMPLETED
IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
Vantive Health LLC n=43
NCT03594110 COMPLETED
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Boehringer Ingelheim n=6,609
NCT04543812 COMPLETED
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
Panion & BF Biotech Inc. n=141
NCT07023016 COMPLETED
Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
National Heart Institute, Egypt n=515
NCT02644941 COMPLETED
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Humacyte, Inc. n=355
NCT05998837 COMPLETED
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy n=34
NCT05585645 COMPLETED
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
Nanogen Pharmaceutical Biotechnology Joint Stock Company n=214
NCT04036253 COMPLETED
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
Bio Sidus SA n=43
NCT04707768 COMPLETED
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Akebia Therapeutics n=456
NCT01651000 COMPLETED
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
OPKO IP Holdings II, Inc. n=213
NCT01704079 COMPLETED
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
OPKO IP Holdings II, Inc. n=216
NCT02278341 COMPLETED
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Astellas Pharma Europe B.V. n=838
NCT06706271 COMPLETED
The Effect of Vitamin D3 Supplementation on Hepcidin and Ferritin Serum Levels in Children With Chronic Kidney Disease
Hasanuddin University n=43
NCT02021318 COMPLETED
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
Astellas Pharma Europe B.V. n=616
NCT01887600 COMPLETED
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Astellas Pharma Europe B.V. n=594
NCT02964936 COMPLETED
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
Astellas Pharma Inc n=100
NCT02988973 COMPLETED
A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Astellas Pharma Inc n=334
NCT02952092 COMPLETED
A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
Astellas Pharma Inc n=303
NCT02780726 COMPLETED
A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
Astellas Pharma Inc n=56
NCT02780141 COMPLETED
A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia
Astellas Pharma Inc n=75
NCT05407389 SUSPENDED
Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study
Kibow Pharma n=600
NCT06016036 COMPLETED
SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease
Shenzhen Salubris Pharmaceuticals Co., Ltd. n=156
NCT05425719 COMPLETED
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
MediBeacon n=249
NCT04456803 COMPLETED
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Sinomune Pharmaceutical Co., Ltd n=239
NCT04741074 TERMINATED
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Geisinger Clinic n=15
NCT03534284 COMPLETED
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
University of Washington n=126
NCT04155125 COMPLETED
A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
PT Kalbe Genexine Biologics n=391
NCT04727528 TERMINATED
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
AstraZeneca n=39
NCT02540993 COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Bayer n=5,734
NCT02945969 COMPLETED
Sodium Lowering and Urinary Protein Reduction Trial
Tulane University School of Public Health and Tropical Medicine n=151
NCT00436748 TERMINATED
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
Amgen n=116
NCT04750460 COMPLETED
Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).
Saint Petersburg State University, Russia n=20
NCT01229072 SUSPENDED
Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.
Azidus Brasil n=60
NCT03710291 TERMINATED
Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
Tricida, Inc. n=1,480
NCT01652872 COMPLETED
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Amgen n=756
NCT03806530 COMPLETED
DIalysis Symptom COntrol-Restless Legs Syndrome Trial
Population Health Research Institute n=52
NCT04410198 COMPLETED
Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants
Kyntra Bio n=203
NCT00888290 COMPLETED
Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects
Albert Einstein College of Medicine n=20
NCT04484857 COMPLETED
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
Kyntra Bio n=283
NCT02865850 COMPLETED
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Akebia Therapeutics n=369
NCT04621331 WITHDRAWN
Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
Kyntra Bio
NCT02892149 COMPLETED
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Akebia Therapeutics n=3,554
NCT02648347 COMPLETED
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
Akebia Therapeutics n=1,751
NCT02680574 COMPLETED
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Akebia Therapeutics n=1,725
NCT02620306 COMPLETED
A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan
Boryung Pharmaceutical Co., Ltd n=351
NCT01155388 TERMINATED
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
AMAG Pharmaceuticals, Inc. n=14
NCT04215120 COMPLETED
Desidustat in the Treatment of Anemia in CKD on Dialysis Patients
Zydus Lifesciences Limited n=392
NCT02273726 COMPLETED
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Kyntra Bio n=741
NCT04764097 WITHDRAWN
Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
Tan Tock Seng Hospital
NCT01750190 COMPLETED
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
Kyntra Bio n=922
NCT02545036 COMPLETED
Combined Western and Traditional Chinese Medicine Daycare for CKD Patients
China Medical University Hospital n=58
NCT04477811 COMPLETED
Comparative Study Evaluating the Effect of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients
Ain Shams University n=40
NCT03036150 COMPLETED
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
AstraZeneca n=4,304
NCT03242018 COMPLETED
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Lexicon Pharmaceuticals n=277
NCT03242252 COMPLETED
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Lexicon Pharmaceuticals n=787
NCT01810939 COMPLETED
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Relypsa, Inc. n=243
NCT03644264 COMPLETED
PA21 Safety and Efficacy in Adult Chinese Subjects
Vifor Fresenius Medical Care Renal Pharma n=286
NCT00985426 COMPLETED
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
Dynavax Technologies Corporation n=521
NCT03299244 COMPLETED
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
Amgen n=637
NCT04027517 COMPLETED
A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.
JW Pharmaceutical n=172
NCT03984760 COMPLETED
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Panion & BF Biotech Inc. n=240
NCT02334488 COMPLETED
Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function
Poitiers University Hospital n=329
NCT02369549 COMPLETED
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=518
NCT01069692 COMPLETED
Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
Novartis n=115
NCT02521181 COMPLETED
The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
Jennifer Gassman, PhD n=194
NCT02940860 COMPLETED
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
Pharmacosmos A/S n=1,538
NCT02138838 TERMINATED
Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
Amgen n=55
NCT02341417 COMPLETED
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
Amgen n=28
NCT04361552 WITHDRAWN
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
NCT02506868 COMPLETED
Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
Biocad n=196
NCT01503736 COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
Panion & BF Biotech Inc. n=183
NCT01452412 COMPLETED
Alkali Therapy in Chronic Kidney Disease
Albert Einstein College of Medicine n=149
NCT01621178 COMPLETED
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
Eli Lilly and Company n=577
NCT02414841 COMPLETED
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Proteon Therapeutics n=696
NCT02358343 COMPLETED
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
University of Washington n=184
NCT02110901 COMPLETED
A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)
Proteon Therapeutics n=349
NCT01195246 COMPLETED
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
Dynavax Technologies Corporation n=155
NCT01628120 COMPLETED
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
Pfizer n=170
NCT03242967 WITHDRAWN
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Akebia Therapeutics
NCT00975000 COMPLETED
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Amgen n=114
NCT01384539 COMPLETED
Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
University of Colorado, Denver n=128
NCT01473407 COMPLETED
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Pfizer n=612
NCT01820767 COMPLETED
Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients
Ricardo Mouzo Mirco n=31
NCT01695759 TERMINATED
Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.
Azidus Brasil n=92
NCT01473420 COMPLETED
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Pfizer n=320
NCT02160145 COMPLETED
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,370
NCT02492620 COMPLETED
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
Denver Nephrologists, P.C. n=200
NCT01628107 COMPLETED
A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Pfizer n=406
NCT01020487 COMPLETED
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)
AbbVie (prior sponsor, Abbott) n=47
NCT02504294 COMPLETED
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
Pfizer n=432
NCT01581073 COMPLETED
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan n=476
NCT02268994 COMPLETED
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
Keryx Biopharmaceuticals n=234
NCT00946998 COMPLETED
Chronic Kidney Disease Antidepressant Sertraline Trial
VA Office of Research and Development n=201
NCT03428594 COMPLETED
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
Chong Kun Dang Pharmaceutical n=403
NCT00384657 WITHDRAWN
Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease
Anemia Working Group Romania
NCT01208818 COMPLETED
Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy
Assistance Publique - Hôpitaux de Paris n=284
NCT01996930 COMPLETED
Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites
University Hospital Birmingham NHS Foundation Trust n=32
NCT01693029 COMPLETED
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Sandoz n=435
NCT01576341 COMPLETED
HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Sandoz n=417
NCT01173848 TERMINATED
Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients
The Cleveland Clinic n=19
NCT01850901 COMPLETED
Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension
UMC Utrecht n=139
NCT01473914 COMPLETED
Trace Element Replenishment Study in Hemodialysis Patients
Marcello Tonelli n=150
NCT01457001 TERMINATED
Clinical Trial on the Use of 25-OH -D Vitamin in Haemodialysis Patients
Italian Society of Nephrology n=284
NCT01191762 COMPLETED
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
Kenneth R. Phelps, M.D. n=30
NCT01180101 COMPLETED
Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease
The Cleveland Clinic n=37
NCT01503021 COMPLETED
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
Rockwell Medical Technologies, Inc. n=718
NCT01478971 COMPLETED
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
Takeda n=184
NCT01219855 COMPLETED
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
OPKO Health, Inc. n=78
NCT01554982 COMPLETED
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Keryx Biopharmaceuticals n=168
NCT01365481 COMPLETED
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
Novartis Pharmaceuticals n=150
NCT01471041 COMPLETED
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
Vital Access Corp. n=54
NCT01377467 COMPLETED
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
Rudolf Wuethrich n=90
NCT01011699 TERMINATED
Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
Centre Hospitalier Universitaire, Amiens n=176
NCT02032095 COMPLETED
The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
Japan Blood Products Organization n=17
NCT00939445 COMPLETED
Short Daily Hemodialysis and Online HDF: Which One is Better?
Bangkok Metropolitan Administration Medical College and Vajira Hospital n=10
NCT01102413 COMPLETED
Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia
Pharmacosmos A/S n=351
NCT01222884 COMPLETED
A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D
Pharmacosmos A/S n=351
NCT00687661 COMPLETED
Queen's University Investigation of Calcification in Chronic Kidney Disease
Queen's University n=25
NCT02027662 COMPLETED
Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Fresenius Medical Care Deutschland GmbH n=61
NCT01742611 COMPLETED
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
Astellas Pharma Inc n=105
NCT00561093 COMPLETED
Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center n=93
NCT01057407 COMPLETED
A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
Astellas Pharma Inc n=110
NCT01017276 COMPLETED
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
Astellas Pharma Inc n=35
NCT00892749 COMPLETED
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
Astellas Pharma Inc n=248
NCT00833768 TERMINATED
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
Genzyme, a Sanofi Company n=5
NCT01736150 COMPLETED
Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
Genzyme, a Sanofi Company n=205
NCT00928811 TERMINATED
Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant
Drexel University College of Medicine n=5
NCT01090037 COMPLETED
TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
Toray Industries, Inc n=892
NCT01837290 COMPLETED
Effects of Dexmedetomidine Premedication on Geriatric Patients With Chronic Renal Failure Undergoing Hip Surgery
Baskent University n=60
NCT01446029 COMPLETED
Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)
Minneapolis Veterans Affairs Medical Center n=601
NCT01742585 COMPLETED
A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
Astellas Pharma Inc n=163
NCT02163954 COMPLETED
ONSET and OFFSET of Ticagrelor in ESRD
Kyunghee University Medical Center n=16
NCT00925587 COMPLETED
Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease
Amgen n=358
NCT00994318 COMPLETED
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Vifor Pharma n=626
NCT01012414 TERMINATED
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
Thomas Jefferson University n=10
NCT01324128 COMPLETED
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Vifor Pharma n=1,059
NCT01464190 COMPLETED
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
Vifor Pharma n=659
NCT02015780 WITHDRAWN
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
Takeda
NCT02005718 COMPLETED
Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD
St George's, University of London n=36
NCT01204528 COMPLETED
Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease
Danderyd Hospital n=36
NCT01173718 COMPLETED
Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access
W.L.Gore & Associates n=138
NCT01562925 COMPLETED
Effect of Red Wine, White Wine and Beer on Contrast-Medium Induced Acute Kidney Injury
University of Cologne n=260
NCT01753466 COMPLETED
The Water Intake Trial: Pilot Phase
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=33
NCT00497146 COMPLETED
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
AbbVie (prior sponsor, Abbott) n=227
NCT01203813 COMPLETED
A Risk Based Approach to Improving Chronic Kidney Disease Management
Brigham and Women's Hospital n=10,000
NCT01232257 COMPLETED
Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)
A.C. Abrahams n=28
NCT00865449 COMPLETED
Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis
Instituto Nacional de Cardiologia Ignacio Chavez n=20
NCT01680198 COMPLETED
Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy n=88
NCT01100203 TERMINATED
Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function
Lene Boesby n=54
NCT01071070 COMPLETED
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
Abbott n=216
NCT00616902 TERMINATED
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
Abbott n=12
NCT00974779 COMPLETED
High-cutoff Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients
Martin-Luther-Universität Halle-Wittenberg n=19
NCT01407601 COMPLETED
Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients
RWTH Aachen University n=53
NCT00895479 TERMINATED
Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence
Ark Therapeutics Ltd n=250
NCT01155765 COMPLETED
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
University of Patras n=70
NCT00727519 COMPLETED
The Effect of Pomegranate Juice on Oxidative Stress in Hemodialysis Patients
Western Galilee Hospital-Nahariya
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only